(2S)-2-(trifluoromethyl)pyrrolidine → (S)-3-[(4-(2-(Trifluoromethyl)pyrrolidin-1-yl)-1,3,5-triazin-2-yl)amino]-benzenemethanesulfonamide
Reaktionsgleichung
Cl[C:2]1[N:7]=[CH:6][N:5]=[C:4]([NH:8][C:9]2[CH:10]=[C:11]([CH2:15][S:16]([NH2:19])(=[O:18])=[O:17])[CH:12]=[CH:13][CH:14]=2)[N:3]=1.[F:20][C:21]([F:28])([F:27])[C@@H:22]1[CH2:26][CH2:25][CH2:24][NH:23]1>>[F:20][C:21]([F:28])([F:27])[C@@H:22]1[CH2:26][CH2:25][CH2:24][N:23]1[C:2]1[N:7]=[CH:6][N:5]=[C:4]([NH:8][C:9]2[CH:10]=[C:11]([CH2:15][S:16]([NH2:19])(=[O:18])=[O:17])[CH:12]=[CH:13][CH:14]=2)[N:3]=1Komponenten
3
Versuchsvorschrift
B16 was prepared following the general procedure reported for B10 using A1 and (S)-2-(trifluoromethyl)pyrrolidine. The title compound (B16) was purified by reverse phase RP-HPLC (column: C18), using H2O (0.1% TFA) and MeOH (0.1% TFA) as eluents. Yield: 58.7 mg (15%), colorless amorphous solid. MS (ES) C15H17F3N6O2S requires: 402. found: 403 (M+H)+.
Aufarbeitung
- customB16 was prepared